04th May 2022 | Pharma Updates
Novartis launches Netflix-like approach to enhance digital doctor engagements
A new video based service to enhance the engagement of doctors. The content is managed my Evermed and Novartis along with rheumatologists and other healthcare professionals.
115 new plants to get manufacturing license in Gujarat
Gujarat’s pharma hub is to evolve soon with 115 new API units, witnessing an investment or 2000 Crores.
Aurobindo Pharma receives FDA approval for Bortezomib, a cancer drug
Eugia Pharma Specialties, a completely owned arm of Aurobindo Pharma, got the final approval by FDA for Bortezomib.
For the second time, USFDA declines approval of drugs tested in China
FDA has declined the approval of drugs tested in China. In March, it declined the Eli Lilly and Innovent Biologics’ cancer drug.
Pharma records best ever performance in export
There has been a positive growth in India’s pharma export in 2021-2022 despite the decline in demand for Covid medicines
AstraZeneca secures delivery patent for Symbicort, sues Mylan
In order to protect Symbicort, its respiratory disease drug, AstraZeneca secured the delivery patent followed by a Lawsuit in opposition to Mylan and Kindeva Drug Delivery.
Bayer's prostate cancer drug earns priority review status
Nubeqa on Tuesday earned FDA’s priority review status, an indication that it will broaden its reach.
